ADA (American Diabetes Association) June 20-24 Obesity Medicines – Lilly Posters and Talks
Lilly Orgorglipron Orforglipron is a novel, oral, non-peptide GLP‑1 receptor agonist, and the ACHIEVE‑1 Phase III data demonstrated efficacy and tolerability comparable to existing injectables Oral Presentation – Lilly will feature its oral GLP‑1 candidate, orforglipron, with topline results from its Phase III ACHIEVE‑1 trial showing positive safety, glycemic control, and weight loss (~8 % at 40 weeks). This […]
STAT+: Lilly’s amylin candidate shows early promise
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss conflicts of interest in the newly appointed ACIP team, are sad to hear of a second death from Sarepta’s gene therapy for Duchenne muscular dystrophy, and see Anne Wojcicki win […]
6 Ways To Reduce Side Effects In Ozempic, Wegovy, Mounjaro & Zepbound
Learn how to reduce side effects from GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound with six expert-backed strategies for better health and long-term success.
D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.–(BUSINESS WIRE)–D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced positive results from DD01-DN-02 study, an ongoing 48-week Phase 2 trial designed to evaluate the efficacy and safety of DD01 (a once-weekly dual GLP1/glucagon receptor agonist) in 67 overweight/obese […]
South Korean biotech’s GLP-1 drug scores MASH win while reducing weight
D&D Pharmatech tested a once-weekly regimen of its dual GLP1/glucagon receptor agonist DD01 in 67 overweight or obese patients with MASH.
A New Obesity Pill May Burn Fat Without Suppressing Appetite
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.